KMT2A and acute myeloid leukemia: t-AML was confirmed by bone marrow aspiration, immunophenotyping, gene mutation and cytogenetic examinations, accompanied by breast cancer susceptibility gene 2 (<i>BRCA2</i>), DNA (cytosine-5)-methyltransferase 3 alpha (<i>DNMT3A</i>), and isocitrate dehydrogenase 2 (<i>IDH2</i>) mutations, and positivity for lysine (K)-specific methyltransferase 2A partial tandem duplication (<i>KMT2A-PTD</i>).